Active Biotech's ANYARA cancer project presented at ASCO in Atlanta
The results obtained fulfill several of the objectives set up for ANYARA development. It has been possible to determine a reproducible induction of the immunostimulatory cytokine Interleukin-2 (IL-2), as a surrogate marker for T lymphocyte activation, in connection with ANYARA injections. Notably, a correlation between IL-2 induction and prolonged survival for renal cancer patients has previously been showed with the first generation of ANYARA. Furthermore, a selective increase of ANYARA-specific T lymphocytes following treatment was observed, which shows that treatment does not only activate the patients' T lymphocytes in general, but also selectively increase the amount of ANYARA reactive T lymphocytes.
This ANYARA study is being performed at the Fox Chase Cancer Center in Philadelphia, in the US, at the Radium Hospital in Oslo, Norway, and at the Christie Hospital, in Manchester, in the UK.
An additional Phase I study within the ANYARA program is currently in progress. It is a combination study of ANYARA and the established chemotherapy drug Taxotere®. The combination study is being conducted in clinics in the US, Denmark and Russia. A Phase II clinical study with renal cancer patients is scheduled to commence before the end of the year.
For further information and to view the full poster "An open-label Phase I study of ABR-217620, a fusion protein of the 5T4 antibody moiety and an engineered superantigen, in patients with non-small cell lung, renal cell or pancreatic cancer," visit www.activebiotech.com.
Lund, June 5, 2006
Active Biotech AB (publ)
President and CEO
Active Biotech AB is a biotechnology company focusing on research and development of pharmaceuticals. Active Biotech has a strong R&D portfolio with pipeline products focused on autoimmune/inflammatory diseases and cancer. Most advanced projects are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, as well as ANYARA for use in cancer immunotherapy with the primary indication non-small cell lung cancer. Further key projects in clinical development comprise the three orally administered compounds TASQ for prostate cancer 57-57 for SLE and RhuDex® for RA. In addition, the preclinical development of the I-3D project is being conducted in cooperation with Chelsea Therapeutics.
Active Biotech AB
Box 724, 220 07 Lund
Tel +46 (0) 46-19 20 00
Fax +46 (0) 46-19 20 50